Positive Phase 1 data shows potential of CK-0045 to improve cardiometabolic risk factors
Cytoki Pharma has revealed positive data from a Phase 1 study evaluating the safety, tolerability and pharmacokinetics of CK-0045, its...
top of page
Browse by category
Search
Browse by tag
bottom of page